Primary Angiitis of the CNS

Primary Angiitis of the CNS (PACNS): A Comprehensive Clinical Guide

Primary Angiitis of the Central Nervous System (PACNS), also historically referred to as primary angiitis of the brain, is a rare, complex, and potentially life-threatening systemic inflammatory vasculitis restricted exclusively to the vessels of the central nervous system (CNS). Unlike secondary vasculitides that may involve the CNS as part of a systemic process (such as Systemic Lupus Erythematosus or Polyarteritis Nodosa), PACNS represents an isolated autoimmune attack on the brain and spinal cord vasculature.

This guide provides an exhaustive review for clinicians, focusing on the diagnostic challenges, pathophysiological mechanisms, and management strategies required to navigate this elusive condition.

1. Clinical Definition and Overview

PACNS is defined as an inflammatory disease of the small-to-medium-sized leptomeningeal and parenchymal arteries of the brain and spinal cord. It is characterized by the absence of systemic vasculitis or any other identifiable cause of angiopathy.

The clinical hallmark of PACNS is its insidious onset, often manifesting as multifocal neurological deficits, cognitive impairment, and chronic headaches. Because the inflammation is confined to the CNS, the lack of systemic symptoms (fever, weight loss, rash, arthralgia) is a key diagnostic discriminator that often leads to significant delays in diagnosis.

Key Epidemiological Characteristics

2. Pathophysiology and Mechanisms

The underlying mechanism of PACNS involves a T-cell-mediated immune response targeting the vessel walls. The process initiates a cascade of inflammatory events that result in vessel wall thickening, stenosis, and subsequent tissue ischemia or hemorrhage.

The Mechanism of Injury

1. Endothelial Activation: Initial insult—potentially triggered by infectious agents or genetic predisposition—leads to the upregulation of adhesion molecules (ICAM-1, VCAM-1).
2. Leukocyte Recruitment: CD4+ and CD8+ T-lymphocytes, along with macrophages, infiltrate the tunica media and adventitia of the vessel walls.
3. Vessel Remodeling: Chronic inflammation leads to the proliferation of smooth muscle cells and the deposition of collagen, causing concentric narrowing of the lumen.
4. Ischemic/Hemorrhagic Sequelae: The resulting stenosis leads to hypoperfusion, micro-infarcts, and potentially the formation of aneurysms, which may rupture, causing intraparenchymal or subarachnoid hemorrhage.

3. Clinical Presentation and Staging

The clinical presentation of PACNS is notoriously polymorphic, which often leads to misdiagnosis as multiple sclerosis, primary brain tumor, or infectious encephalitis.

Standard Clinical Presentation

• Headache: The most common symptom, typically chronic, progressive, and resistant to standard analgesics.
• Cognitive Dysfunction: Encephalopathy, progressive dementia, or executive dysfunction.
• Focal Neurological Deficits: Hemiparesis, aphasia, visual field disturbances, or cranial nerve palsies.
• Seizures: Often focal, occurring in approximately 25% of patients.
• Stroke-like Episodes: Transient ischemic attacks (TIAs) or completed strokes in young patients without traditional cardiovascular risk factors.

Clinical Staging/Grading (Calabrese Criteria)

While there is no formal international staging system for PACNS, clinicians utilize the Calabrese and Mallek criteria for diagnosis:
1. Acquired neurological deficit: Unexplained by other systemic or localized processes.
2. Angiographic or Histopathological evidence: Classic changes of vasculitis in the CNS.
3. Exclusion of systemic vasculitis: Through rigorous serological and imaging workup.

4. Diagnostic Workup and Differential Diagnosis

Diagnosing PACNS requires a "rule-out" strategy. The clinician must exclude mimics before confirming the diagnosis.

Key Diagnostic Tests

• MRI Brain (with/without contrast): Sensitivity is high (>90%). Findings include multiple ischemic infarcts in different vascular territories, leptomeningeal enhancement, or parenchymal signal abnormalities.
• Cerebrospinal Fluid (CSF) Analysis: Often shows pleocytosis (lymphocytic) and elevated protein levels. The presence of oligoclonal bands is possible but non-specific.
• Digital Subtraction Angiography (DSA): The "Gold Standard" for visualization, though it has limited sensitivity for small-vessel PACNS. Findings include "beading" (alternating areas of stenosis and dilation).
• Brain/Leptomeningeal Biopsy: The definitive diagnostic procedure. Requires open biopsy with wedge resection including leptomeninges and underlying cortex.

Differential Diagnosis Table

5. Risks, Side Effects, and Contraindications

The management of PACNS involves aggressive immunosuppressive therapy, which carries substantial risks.

Standard Therapeutic Regimen

• Induction Phase: High-dose intravenous corticosteroids (Methylprednisolone) followed by oral tapering. If the condition is severe or refractory, Cyclophosphamide is the standard adjunct.
• Maintenance Phase: Azathioprine, Mycophenolate Mofetil, or Rituximab.

Risks and Side Effects of Treatment

• Immunosuppression: Increased risk of opportunistic infections (CMV, fungal, TB).
• Cyclophosphamide Toxicity: Hemorrhagic cystitis, infertility, and secondary malignancies (bladder cancer).
• Corticosteroid Toxicity: Osteoporosis, hyperglycemia, hypertension, and psychiatric disturbances.

6. Long-Term Prognosis

The prognosis of PACNS has improved significantly with the advent of aggressive immunosuppressive regimens. However, patients often experience residual neurological deficits, cognitive decline, or epilepsy.

• Mortality: Historically high, now reduced to <10% with timely diagnosis and treatment.
• Relapse Rate: Approximately 25-30% of patients experience a relapse, necessitating long-term monitoring and maintenance therapy.
• Functional Outcome: Early initiation of treatment is the single most important factor in preserving cognitive and functional independence.

7. Frequently Asked Questions (FAQ)

1. Is PACNS the same as Reversible Cerebral Vasoconstriction Syndrome (RCVS)?
No. While they share similar angiographic features, RCVS is typically characterized by thunderclap headaches and spontaneous resolution of vascular narrowing within 3 months, whereas PACNS requires long-term immunosuppression.

2. Is a brain biopsy always necessary?
It is the gold standard for diagnosis. However, if imaging and clinical findings are highly classic and other systemic causes are excluded, some clinicians may initiate treatment empirically, though this is controversial.

3. What is the role of Rituximab in PACNS?
Rituximab is increasingly used as a second-line or steroid-sparing agent, particularly in cases that are refractory to standard cyclophosphamide or where cyclophosphamide is contraindicated.

4. Can PACNS affect the spinal cord?
Yes, though rare, PACNS can involve the spinal cord (primary angiitis of the CNS of the spinal cord), leading to myelopathy.

5. How long should treatment last?
Treatment is typically continued for at least 12–24 months, with careful monitoring for clinical and radiological stability before tapering.

6. Are there specific biomarkers for PACNS?
Currently, there is no single blood biomarker. Diagnosis relies on a combination of CSF analysis, imaging, and biopsy.

7. Why is the biopsy often negative?
The inflammatory lesions in PACNS are often "patchy" (skip lesions). A biopsy may miss the affected area, leading to a false-negative result.

8. Is PACNS hereditary?
There is no evidence of a direct hereditary link, though like many autoimmune conditions, a genetic predisposition may exist.

9. Can PACNS cause sudden death?
Yes, if left untreated, rupture of a vasculitic aneurysm or severe brainstem involvement can lead to fatal outcomes.

10. What is the difference between cPACNS and adult PACNS?
cPACNS (childhood primary angiitis of the CNS) is often categorized into small-vessel and medium/large-vessel subtypes, with different prognostic implications and a higher frequency of stroke-like presentations.

Final Clinical Perspective

Primary Angiitis of the CNS remains one of the most challenging diagnoses in clinical neurology. The key to successful outcomes lies in a high index of suspicion, timely utilization of high-resolution neuroimaging, and the courage to pursue a brain biopsy when clinical uncertainty persists. By adhering to rigorous exclusion criteria and employing structured immunosuppressive protocols, clinicians can significantly alter the trajectory of this devastating disease.

Disclaimer: This guide is for educational purposes for healthcare professionals and does not constitute medical advice. Always refer to current institutional protocols and the latest peer-reviewed clinical guidelines when managing patients with suspected vasculitis.